Iodine (125I) human albumin
| Clinical data | |
|---|---|
| Trade names | Jeanatope |
| AHFS/Drugs.com | FDA Professional Drug Information |
| Routes of administration | Intravenous injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | ~14 days |
| Excretion | via kidneys |
| Identifiers | |
| PubChem SID | |
| DrugBank | |
| UNII | |
| KEGG | |
Iodine (125I) human albumin (trade name Jeanatope) is human serum albumin iodinated with iodine-125, typically injected to aid in the determination of total blood and plasma volume.[1][2]
Iodine-131 iodinated albumin (trade name Volumex) is used for the same purposes.[3]
Medical uses
[edit]Iodine (125I) human albumin is used to determine a person's blood volume. For this purpose, a defined amount of radioactivity in form of this drug is injected into a vein, and blood samples are drawn from a different body location after five and fifteen minutes. From the radioactivity of these samples, the original radioactivity per blood volume can be calculated; and knowing the total amount of radioactivity injected, one can calculate the total blood volume.[1]
It can also be used to calculate the blood plasma volume using a similar method. The main difference is that the drawn blood sample has to be centrifuged to separate the plasma from the blood cells.[1]
Contraindications
[edit]The US Food and Drug Administration lists no contraindications for this drug.[1]
Adverse effects
[edit]There is a theoretical possibility of allergic reactions after repeated use of this medication.[1]
Pharmacokinetics
[edit]Iodine-125 is a radioactive isotope of iodine that decays by electron capture with a physical half-life of 60.14 days. The biological half-life in normal individuals for iodine (125I) human albumin has been reported to be approximately 14 days. Its radioactivity is excreted almost exclusively via the kidneys.[1]